JP2018504459A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504459A5 JP2018504459A5 JP2017557489A JP2017557489A JP2018504459A5 JP 2018504459 A5 JP2018504459 A5 JP 2018504459A5 JP 2017557489 A JP2017557489 A JP 2017557489A JP 2017557489 A JP2017557489 A JP 2017557489A JP 2018504459 A5 JP2018504459 A5 JP 2018504459A5
- Authority
- JP
- Japan
- Prior art keywords
- epitope
- cll1
- seq
- antigen receptor
- chimeric antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201570044 | 2015-01-26 | ||
| DKPA201570044 | 2015-01-26 | ||
| PCT/EP2016/051469 WO2016120218A1 (en) | 2015-01-26 | 2016-01-25 | ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018504459A JP2018504459A (ja) | 2018-02-15 |
| JP2018504459A5 true JP2018504459A5 (Direct) | 2019-03-07 |
| JP6779909B2 JP6779909B2 (ja) | 2020-11-04 |
Family
ID=52396337
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557491A Pending JP2018504145A (ja) | 2015-01-26 | 2016-01-25 | 再発性／難治性急性骨髄性リンパ腫または芽球性形質細胞様樹状細胞新生物を処置するための、ｃｄ１２３に結合するキメラ抗原受容体を賦与された、操作されたｔ細胞受容体ノックアウト免疫細胞 |
| JP2017557487A Active JP6884709B2 (ja) | 2015-01-26 | 2016-01-25 | 操作された免疫細胞の選別／枯渇のための、ｍＡｂが推進するキメラ抗原受容体系 |
| JP2017557490A Withdrawn JP2018504144A (ja) | 2015-01-26 | 2016-01-25 | Ｃｌｌ１特異的多鎖キメラ抗原受容体 |
| JP2017557488A Pending JP2018504143A (ja) | 2015-01-26 | 2016-01-25 | がん免疫治療のための抗ｈｓｐ７０特異的キメラ抗原受容体（ｃａｒ） |
| JP2017557489A Active JP6779909B2 (ja) | 2015-01-26 | 2016-01-25 | がん免疫治療のための抗ＣＬＬ１特異的単鎖キメラ抗原受容体（ｓｃＣＡＲ） |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557491A Pending JP2018504145A (ja) | 2015-01-26 | 2016-01-25 | 再発性／難治性急性骨髄性リンパ腫または芽球性形質細胞様樹状細胞新生物を処置するための、ｃｄ１２３に結合するキメラ抗原受容体を賦与された、操作されたｔ細胞受容体ノックアウト免疫細胞 |
| JP2017557487A Active JP6884709B2 (ja) | 2015-01-26 | 2016-01-25 | 操作された免疫細胞の選別／枯渇のための、ｍＡｂが推進するキメラ抗原受容体系 |
| JP2017557490A Withdrawn JP2018504144A (ja) | 2015-01-26 | 2016-01-25 | Ｃｌｌ１特異的多鎖キメラ抗原受容体 |
| JP2017557488A Pending JP2018504143A (ja) | 2015-01-26 | 2016-01-25 | がん免疫治療のための抗ｈｓｐ７０特異的キメラ抗原受容体（ｃａｒ） |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US20180051089A1 (Direct) |
| EP (5) | EP3250606B1 (Direct) |
| JP (5) | JP2018504145A (Direct) |
| KR (3) | KR102661969B1 (Direct) |
| CN (5) | CN113968914A (Direct) |
| AU (5) | AU2016212158B2 (Direct) |
| BR (2) | BR112017015453A2 (Direct) |
| CA (4) | CA2973532A1 (Direct) |
| DK (2) | DK3250606T3 (Direct) |
| ES (2) | ES2842212T3 (Direct) |
| IL (3) | IL252937B (Direct) |
| MX (3) | MX2017009349A (Direct) |
| RU (3) | RU2732925C2 (Direct) |
| WO (5) | WO2016120218A1 (Direct) |
Families Citing this family (165)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| CN106103490B (zh) * | 2014-03-19 | 2020-03-03 | 塞勒克提斯公司 | 用于癌症免疫疗法的cd123特异性嵌合抗原受体 |
| PE20171653A1 (es) | 2015-04-13 | 2017-11-13 | Pfizer | Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11420136B2 (en) | 2016-10-19 | 2022-08-23 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| JP2018522907A (ja) * | 2015-08-11 | 2018-08-16 | セレクティスＣｅｌｌｅｃｔｉｓ | Ｃｄ３８抗原を標的とするためおよびｃｄ３８遺伝子を不活化するために操作された、免疫療法用の細胞 |
| CN108472365A (zh) | 2015-10-30 | 2018-08-31 | 艾丽塔生物治疗剂公司 | 用于肿瘤转导的组合物和方法 |
| MX2018005315A (es) * | 2015-10-30 | 2018-08-14 | Aleta Biotherapeutics Inc | Composiciones y metodos para el tratamiento del cancer. |
| CN105331586B (zh) * | 2015-11-20 | 2020-09-15 | 上海细胞治疗研究院 | 一种包含高效杀伤启动机制的肿瘤精准t细胞及其用途 |
| EP3380524A4 (en) * | 2015-11-24 | 2019-07-24 | Cellerant Therapeutics, Inc. | ANTI-CLL-1 HUMANIZED ANTIBODIES |
| HK1257295A1 (zh) | 2015-12-04 | 2019-10-18 | Novartis Ag | 用於免疫肿瘤学的组合物和方法 |
| EP3202783A1 (en) * | 2016-02-02 | 2017-08-09 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Engineered antigen presenting cells and uses thereof |
| JP7250519B2 (ja) | 2016-03-23 | 2023-04-03 | ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） | Ｐｄ－１及び４－１ｂｂの融合タンパク質 |
| US11104738B2 (en) | 2016-04-04 | 2021-08-31 | Hemogenyx Pharmaceuticals Llc | Monoclonal antibodies to human FLT3/FLK2 receptor protein |
| WO2017176760A2 (en) | 2016-04-04 | 2017-10-12 | Vladislav Sandler | Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| KR102652827B1 (ko) | 2016-06-08 | 2024-04-01 | 프레시전 인코포레이티드 | Cd33 특이적 키메라 항원 수용체 |
| JP7195154B2 (ja) | 2016-07-06 | 2022-12-23 | セレクティス | 初代免疫細胞における逐次遺伝子編集 |
| EP3500293A4 (en) * | 2016-08-19 | 2020-08-19 | Janssen Biotech, Inc. | METHODS OF TREATING CROHN'S DISEASE WITH AN ANTI-NKG2D ANTIBODY |
| US20190307799A1 (en) | 2016-09-23 | 2019-10-10 | The Regents Of The University Of Michigan | Engineered lymphocytes |
| AU2017338846B2 (en) * | 2016-10-04 | 2020-09-24 | Precision Biosciences, Inc. | Co-stimulatory domains for use in genetically-modified cells |
| WO2018073394A1 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Cell death inducing chimeric antigen receptors |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| EP3559038B1 (en) | 2016-12-21 | 2022-12-14 | The United States of America as represented by The Secretary Department of Health and Human Services | Human monoclonal antibodies specific for flt3 and uses thereof |
| WO2018115189A1 (en) | 2016-12-21 | 2018-06-28 | Cellectis | Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy |
| AU2017384900B2 (en) | 2016-12-28 | 2020-12-10 | GC Cell Corporation | Chimeric antigen receptor and natural killer cells expressing same |
| CN108250301A (zh) * | 2016-12-29 | 2018-07-06 | 天津天锐生物科技有限公司 | 一种多靶点嵌合抗原受体 |
| JP7386082B2 (ja) | 2017-02-28 | 2023-11-24 | ブイオーアール バイオファーマ インコーポレーテッド | 系統特異的タンパク質の阻害のための組成物および方法 |
| CN110832075A (zh) | 2017-03-22 | 2020-02-21 | 诺华股份有限公司 | 用于免疫肿瘤学的组合物和方法 |
| CN110382542B (zh) * | 2017-03-29 | 2023-06-09 | 豪夫迈·罗氏有限公司 | 针对共刺激性tnf受体的双特异性抗原结合分子 |
| JP7314115B2 (ja) | 2017-03-31 | 2023-07-25 | セレクティス ソシエテ アノニム | ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞 |
| AU2018243753A1 (en) * | 2017-04-01 | 2019-10-10 | Avm Biotechnology, Llc | Replacement of cytotoxic preconditioning before cellular immunotherapy |
| CN110914289B (zh) | 2017-05-12 | 2024-05-14 | 克里斯珀医疗股份公司 | 用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途 |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| MY201327A (en) * | 2017-06-02 | 2024-02-16 | Pfizer | Chimeric antigen receptors targeting flt3 |
| EP4681734A2 (en) | 2017-06-07 | 2026-01-21 | Precigen, Inc. | Expression of novel cell tags |
| CN111247242B (zh) * | 2017-06-21 | 2024-07-19 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(CARs)、组合物及其使用方法 |
| AU2018292181B2 (en) | 2017-06-30 | 2025-04-10 | Cellectis | Cellular immunotherapy for repetitive administration |
| CA3069558A1 (en) * | 2017-07-09 | 2019-01-17 | Biosight Ltd. | Combination cancer therapy |
| US11479606B2 (en) | 2017-07-20 | 2022-10-25 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Compositions and methods for targeting CD33-expressing cancers |
| WO2019016360A1 (en) | 2017-07-21 | 2019-01-24 | Cellectis | MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT |
| EP4582146A2 (en) * | 2017-07-25 | 2025-07-09 | Board of Regents, The University of Texas System | Enhanced chimeric antigen receptors and use thereof |
| WO2019020733A1 (en) | 2017-07-26 | 2019-01-31 | Cellectis | METHODS OF IMMUNE CELL SELECTION OF THE ANTIGEN-DEPENDENT CHIMERIC ANTIGENIC RECEPTOR (CAR) |
| KR20200071079A (ko) * | 2017-09-27 | 2020-06-18 | 유니버시티 오브 써던 캘리포니아 | 공동-자극을 위한 신규한 플랫폼, 신규한 car 설계 및 입양 세포 치료를 위한 다른 향상 |
| WO2019072824A1 (en) | 2017-10-09 | 2019-04-18 | Cellectis | IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| WO2019098682A1 (ko) | 2017-11-14 | 2019-05-23 | 앱클론(주) | 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체 |
| CN109836496A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种靶向cd317的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN109837303A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种敲除pd1的靶向cd317的嵌合抗原受体t细胞及其制备方法和应用 |
| WO2019106163A1 (en) | 2017-12-01 | 2019-06-06 | Cellectis | Reprogramming of genetically engineered primary immune cells |
| EP3725092A4 (en) | 2017-12-14 | 2021-09-22 | FloDesign Sonics, Inc. | DRIVE AND CONTROL UNIT FOR ACOUSTIC CONVERTER |
| CA3086267A1 (en) | 2017-12-29 | 2019-07-04 | Cellectis | Method for improving production of car t cells |
| CN109608548A (zh) * | 2017-12-29 | 2019-04-12 | 郑州大学第附属医院 | 基于人源cd20抗体的嵌合抗原受体、慢病毒表达载体及其应用 |
| KR20200115511A (ko) * | 2017-12-29 | 2020-10-07 | 시티 오브 호프 | 메디토프-이용 가능한 t 세포 |
| WO2019129850A1 (en) | 2017-12-29 | 2019-07-04 | Cellectis | Off-the-shelf engineered cells for therapy |
| AU2019207635A1 (en) * | 2018-01-09 | 2020-08-06 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Compositions and methods for targeting CLEC12A-expressing cancers |
| KR20250040087A (ko) | 2018-02-01 | 2025-03-21 | 화이자 인코포레이티드 | Cd70을 표적으로 하는 키메라 항원 수용체 |
| PE20251579A1 (es) | 2018-02-01 | 2025-06-16 | Pfizer | Anticuerpos especificos para cd70 y sus usos |
| AR114273A1 (es) | 2018-03-02 | 2020-08-12 | Allogene Therapeutics Inc | Receptores inducibles de citoquina quimérica |
| SG11202008796VA (en) * | 2018-03-14 | 2020-10-29 | The United States Of America As Represented By The Secretary | Anti-cd33 chimeric antigen receptors and their uses |
| US20210070860A1 (en) * | 2018-03-21 | 2021-03-11 | Dana-Farber Cancer Institute, Inc. | Fc variant compositions and methods of use thereof |
| CN108530536B (zh) * | 2018-03-27 | 2021-08-13 | 刘爽 | Cart-cd123及其制备与应用 |
| CN108531457A (zh) * | 2018-04-10 | 2018-09-14 | 杭州荣泽生物科技有限公司 | 一种Cas9/RNP敲除T细胞PD-1和LAG3基因及制备CAR-T细胞的方法 |
| WO2019197678A1 (en) | 2018-04-13 | 2019-10-17 | Sangamo Therapeutics France | Chimeric antigen receptor specific for interleukin-23 receptor |
| BR112020022879A2 (pt) | 2018-05-11 | 2021-02-23 | Crispr Therapeutics Ag | métodos e composições para tratamento de câncer |
| EP3796935A4 (en) | 2018-05-23 | 2022-03-16 | The Jackson Laboratory | ANTI-OX40 ANTIBODIES AND METHODS OF USE |
| EP3802619A1 (en) | 2018-06-08 | 2021-04-14 | F. Hoffmann-La Roche AG | Peptidic linker with reduced post-translational modification |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| WO2019246593A2 (en) * | 2018-06-22 | 2019-12-26 | Fred Hutchinson Cancer Research Center | Compositions and methods to target cll-1 and cd123 for the treatment of acute myeloid leukemia and related disorders |
| US20210268028A1 (en) * | 2018-07-02 | 2021-09-02 | Cellectis | Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml |
| US20210308171A1 (en) * | 2018-08-07 | 2021-10-07 | The Broad Institute, Inc. | Methods for combinatorial screening and use of therapeutic targets thereof |
| GB201813178D0 (en) * | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
| WO2020047164A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma, Inc | Genetically engineered hematopoietic stem cells and uses thereof |
| CN109503716B (zh) * | 2018-10-08 | 2021-04-27 | 浙江生研生物科技有限公司 | 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| SG11202104240TA (en) * | 2018-10-26 | 2021-05-28 | Cafa Therapeutics Ltd | Cll1-targeting antibody and application thereof |
| EP3873500A4 (en) | 2018-10-31 | 2023-01-11 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| EP3873540A4 (en) | 2018-10-31 | 2022-07-27 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| MX2021006395A (es) | 2018-12-01 | 2021-07-15 | Allogene Therapeutics Inc | Receptores de antigenos quimericos dirigidos al antigeno de maduracion de celulas b y sus metodos de uso. |
| PH12021551285A1 (en) | 2018-12-18 | 2022-05-02 | Boehringer Ingelheim Io Canada Inc | Flt3 agonist antibodies and uses thereof |
| TW202045547A (zh) | 2019-03-01 | 2020-12-16 | 美商艾洛基因醫療公司 | 靶向ｄｌｌ３的嵌合抗原受體和結合劑 |
| CN113508128B (zh) | 2019-03-01 | 2025-11-04 | 艾洛基治疗公司 | 组成型活性嵌合细胞因子受体 |
| JP7633937B2 (ja) | 2019-03-01 | 2025-02-20 | アロジーン セラピューティクス，インコーポレイテッド | Ｐｄ－１外部ドメインを担持するキメラサイトカイン受容体 |
| WO2020180882A1 (en) | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| EP3937974A1 (en) * | 2019-03-11 | 2022-01-19 | Leucid Bio Ltd | Muc1 parallel car (pcar) therapeutic agents |
| CN113853390B (zh) * | 2019-03-15 | 2025-04-25 | 罗格斯新泽西州立大学 | Cd147嵌合抗原受体和使用方法 |
| EP3941488B1 (en) | 2019-03-21 | 2025-05-14 | Allogene Therapeutics, Inc. | Methods for enhancing tcr alpha beta+ cell depletion efficiency |
| CN120944827A (zh) * | 2019-03-27 | 2025-11-14 | 宾夕法尼亚大学董事会 | Tn-MUC1嵌合抗原受体(CAR)T细胞疗法 |
| AU2020271123A1 (en) | 2019-04-10 | 2021-11-25 | Elevatebio Technologies, Inc. | FLT3-specific chimeric antigen receptors and methods of using the same |
| US11896617B2 (en) | 2019-04-26 | 2024-02-13 | Allogene Therapeutics, Inc. | Polynucleotides encoding rituximab-resistant chimeric antigen receptors |
| KR20220004028A (ko) | 2019-04-26 | 2022-01-11 | 알로젠 테라퓨틱스 인코포레이티드 | 동종 car t 세포를 제조하는 방법 |
| AU2020267057A1 (en) | 2019-04-30 | 2021-11-18 | Crispr Therapeutics Ag | Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19 |
| CA3143108A1 (en) * | 2019-06-19 | 2020-12-24 | Julius-Maximilians-Universitat Wurzburg | Ultramodular igg3-based spacer domain and multi-function site for implementation in chimeric antigen receptor design |
| CN112111013A (zh) * | 2019-06-22 | 2020-12-22 | 南京北恒生物科技有限公司 | 一种靶向claudin 18.2的通用型嵌合抗原受体T细胞、构建方法及其用途 |
| WO2021007266A1 (en) * | 2019-07-09 | 2021-01-14 | Hemogenyx Llc | Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies |
| BR112022003553A2 (pt) | 2019-08-30 | 2022-05-24 | Allogene Therapeutics Inc | Receptores de citocina quiméricos compreendendo domínios de ligação a tgf beta |
| CA3153197A1 (en) | 2019-10-03 | 2021-04-08 | Ryan T. Gill | Crispr systems with engineered dual guide nucleic acids |
| EP3808766A1 (en) | 2019-10-15 | 2021-04-21 | Sangamo Therapeutics France | Chimeric antigen receptor specific for interleukin-23 receptor |
| WO2021130250A1 (en) | 2019-12-23 | 2021-07-01 | Cellectis | New mesothelin specific chimeric antigen receptors (car) for solid tumors cancer immunotherapy |
| US20230112444A1 (en) | 2020-01-16 | 2023-04-13 | Springworks Therapeutics, Inc. | Combination therapies of chimeric antigen receptors targeting b-cell maturation antigen and gamma secretase inhibitors |
| PE20221757A1 (es) | 2020-02-24 | 2022-11-11 | Allogene Therapeutics Inc | Celulas t con car de bcma con actividades mejoradas |
| CA3170369A1 (en) | 2020-03-05 | 2022-04-14 | Michal Shahar | Methods and compositions for treating cancer with immune cells |
| BR112022017815A2 (pt) * | 2020-03-06 | 2022-11-29 | Purdue Research Foundation | Métodos, compostos e composições para modificar a atividade de células car-t |
| WO2021188599A1 (en) | 2020-03-16 | 2021-09-23 | University Of Southern California | Novel antigen binding domains and synthetic antigen receptors incorporating the same |
| CA3169301A1 (en) * | 2020-03-18 | 2021-09-23 | Shyr Jiann Li | Anti-il4 receptor antibodies for veterinary use |
| US12054531B2 (en) | 2020-03-20 | 2024-08-06 | Lyell Immunopharma, Inc. | Recombinant cell surface markers |
| US20230128075A1 (en) * | 2020-03-27 | 2023-04-27 | Board Of Regents, The University Of Texas System | Monoclonal antibodies targeting hsp70 and therapeutic uses thereof |
| AU2021268253A1 (en) | 2020-05-06 | 2022-12-08 | Cellectis S.A. | Methods for targeted insertion of exogenous sequences in cellular genomes |
| WO2021225399A1 (ko) * | 2020-05-08 | 2021-11-11 | (주)에스엠티바이오 | 암 치료를 위한 키메라 항원 수용체 |
| GB202007842D0 (en) * | 2020-05-26 | 2020-07-08 | Quell Therapeutics Ltd | Polypeptide useful in adoptive cell therapy |
| CN113735973B (zh) * | 2020-05-28 | 2023-05-09 | 中国科学院微生物研究所 | 一种抗SIRPα抗体及其应用 |
| WO2021241729A1 (ja) * | 2020-05-29 | 2021-12-02 | ブライトパス・バイオ株式会社 | 抗ｃｄ７３抗体およびその用途 |
| US20230228739A1 (en) | 2020-07-03 | 2023-07-20 | Cellectis S.A. | Method for determining potency of chimeric antigen receptor expressing immune cells |
| KR20230040331A (ko) | 2020-07-21 | 2023-03-22 | 알로젠 테라퓨틱스 인코포레이티드 | 강화된 신호 전달 및 활성을 갖는 키메라 항원 수용체 및 이의 용도 |
| WO2022018262A1 (en) | 2020-07-24 | 2022-01-27 | Cellectis S.A. | T-cells expressing immune cell engagers in allogenic settings |
| WO2022032299A1 (en) * | 2020-08-07 | 2022-02-10 | Neogene Therapeutics B.V. | Methods to enrich genetically engineered t cells |
| CN112079927B (zh) * | 2020-09-18 | 2021-12-28 | 西安桑尼赛尔生物医药有限公司 | 一种cd123结合蛋白、含其的car及其应用 |
| WO2022061837A1 (en) * | 2020-09-27 | 2022-03-31 | Jiangsu Cell Tech Medical Research Institute Co., Ltd. | Fibronectin extra domain b (edb) -specific car-t for cancer |
| CN113234169B (zh) * | 2020-12-11 | 2022-11-01 | 广州百暨基因科技有限公司 | 靶向cll1嵌合抗原受体及其应用 |
| CN113248622B (zh) * | 2020-12-11 | 2022-11-01 | 广州百暨基因科技有限公司 | 一种靶向cll1和nkg2d配体的双靶点嵌合抗原受体及其应用 |
| CN113896795B (zh) * | 2020-12-11 | 2022-07-15 | 广州百暨基因科技有限公司 | 抗cll1抗体及其应用 |
| AU2021401934A1 (en) | 2020-12-14 | 2023-06-22 | Allogene Therapeutics, Inc. | Methods and reagents for characterizing car t cells for therapies |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| WO2022140388A1 (en) | 2020-12-21 | 2022-06-30 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
| WO2022144836A1 (en) | 2020-12-31 | 2022-07-07 | Sanofi | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
| CN112694532B (zh) * | 2021-01-12 | 2023-04-18 | 倍而达药业（苏州）有限公司 | 抗Siglec-15的抗体或其抗原结合片段及应用 |
| CN112661816B (zh) * | 2021-01-13 | 2022-10-11 | 江西省人民医院 | 用于利妥昔单抗血药浓度检测的人工抗原及试剂盒 |
| WO2022165133A1 (en) | 2021-01-28 | 2022-08-04 | Allogene Therapeutics, Inc. | Methods for transducing immune cells |
| CA3204417A1 (en) | 2021-01-29 | 2022-08-04 | Allogene Therapeutics, Inc. | Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products |
| WO2022182891A1 (en) | 2021-02-25 | 2022-09-01 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| EP4298212A1 (en) | 2021-02-25 | 2024-01-03 | Artisan Development Labs, Inc. | Compositions and methods for targeting, editing, or modifying genes |
| AU2022267804A1 (en) * | 2021-04-30 | 2023-12-14 | Cellectis S.A. | New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy |
| EP4419672A2 (en) | 2021-06-01 | 2024-08-28 | Artisan Development Labs, Inc. | Compositions and methods for targeting, editing, or modifying genes |
| WO2022266075A1 (en) | 2021-06-14 | 2022-12-22 | Caribou Biosciences, Inc. | Methods and materials for treating cancer using car constructs with an intracellular domain comprising a stap domain and a kinase domain or a stap domain and a phosphatase domain |
| CA3221957A1 (en) | 2021-06-15 | 2022-12-22 | Allogene Therapeutics, Inc. | Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistence |
| CN115477705B (zh) * | 2021-06-16 | 2024-02-23 | 四川大学华西医院 | 一种基于颗粒酶b构建的嵌合抗原受体免疫细胞制备及其应用 |
| CN115477704B (zh) * | 2021-06-16 | 2024-02-23 | 四川大学华西医院 | 一种基于lox1构建的嵌合抗原受体免疫细胞制备及其应用 |
| US20250034558A1 (en) | 2021-06-18 | 2025-01-30 | Artisan Development Labs, Inc. | Compositions and methods for targeting, editing or modifying human genes |
| WO2023020471A1 (en) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Cd123-targetting antibodies and uses thereof in cancer therapies |
| MX2024002590A (es) | 2021-09-01 | 2024-03-22 | Springworks Therapeutics Inc | Sintesis de nirogacestat. |
| CN118339187A (zh) * | 2021-12-31 | 2024-07-12 | 上海宏成药业有限公司 | 抗pd-1抗体及其用途 |
| US20250388896A1 (en) | 2022-03-01 | 2025-12-25 | Celyntra Therapeutics Sa | Composition and methods for transgene insertion |
| EP4499680A1 (en) | 2022-03-29 | 2025-02-05 | Allogene Therapeutics, Inc. | Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals |
| WO2023201238A1 (en) | 2022-04-11 | 2023-10-19 | Vor Biopharma Inc. | Binding agents and methods of use thereof |
| EP4532023A1 (en) | 2022-05-27 | 2025-04-09 | Sanofi | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
| EP4562134A1 (en) | 2022-07-29 | 2025-06-04 | Allogene Therapeutics, Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
| WO2024051751A1 (zh) * | 2022-09-06 | 2024-03-14 | 河北森朗生物科技有限公司 | 抗cd123的纳米抗体、嵌合抗原受体及其应用 |
| KR20250117488A (ko) * | 2022-09-20 | 2025-08-04 | 다나-파버 캔서 인스티튜트 인크. | 치료제의 표적화된 분해 및 전달을 위한 수용체-매개 내포작용 |
| CN118240086B (zh) * | 2022-10-08 | 2025-05-09 | 东莞市朋志生物科技有限公司 | 抗纤维蛋白降解产物抗体、检测纤维蛋白降解产物的试剂和试剂盒 |
| TW202440623A (zh) | 2022-11-28 | 2024-10-16 | 美商艾洛基因醫療公司 | 靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途 |
| WO2024121385A1 (en) | 2022-12-09 | 2024-06-13 | Cellectis S.A. | Two-dose regimen in immunotherapy |
| WO2024238565A1 (en) | 2023-05-15 | 2024-11-21 | Vor Biopharma Inc. | Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof |
| CN117783521B (zh) * | 2023-11-23 | 2025-03-04 | 中国农业科学院兰州兽医研究所 | 检测非洲猪瘟病毒p30蛋白抗体的竞争ELISA试剂盒 |
| CN119874909B (zh) * | 2023-12-21 | 2025-11-04 | 华润生物医药有限公司 | 抗trem2抗体及其用途 |
| WO2025233825A1 (en) * | 2024-05-06 | 2025-11-13 | Janssen Pharmaceutica Nv | Enrichment of cells expressing a bird linker |
Family Cites Families (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US20030229208A1 (en) | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DE69233254T2 (de) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanisierter Heregulin Antikörper |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| CA2103887C (en) | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| AU6704794A (en) | 1993-04-13 | 1994-11-08 | Sloan-Kettering Institute For Cancer Research | Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| WO1997033988A1 (en) | 1996-03-12 | 1997-09-18 | Sloan-Kettering Institute For Cancer Research | Double mutants of dihydrofolate reductase and methods of using same |
| ATE373078T1 (de) | 2000-02-24 | 2007-09-15 | Xcyte Therapies Inc | Gleichzeitige stimulation und konzentration von zellen |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| ATE430161T1 (de) | 2000-09-13 | 2009-05-15 | Multimmune Gmbh | Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung |
| EP1334188B1 (en) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| MXPA05004712A (es) | 2002-11-07 | 2005-11-23 | Immunogen Inc | Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos. |
| RS20100366A (sr) * | 2002-12-16 | 2011-04-30 | Genentech, Inc. | Varijante imunoglobulina i njihova upotreba |
| CN1826408B (zh) | 2003-03-14 | 2011-01-26 | 塞托·帕尔斯科技公司 | 大容量离体电穿孔法 |
| WO2005000894A2 (en) * | 2003-06-25 | 2005-01-06 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
| AU2004255216B2 (en) | 2003-07-01 | 2010-08-19 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| CA2536238C (en) | 2003-08-18 | 2015-04-07 | Medimmune, Inc. | Humanization of antibodies |
| CA2537055A1 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| EP2070947B1 (en) | 2003-12-05 | 2014-06-11 | multimmune GmbH | Therapeutic and diagnostic anti-Hsp70 antibodies |
| US8101722B2 (en) * | 2004-02-16 | 2012-01-24 | Micromet Ag | Less immunogenic binding molecules |
| WO2006020258A2 (en) | 2004-07-17 | 2006-02-23 | Imclone Systems Incorporated | Novel tetravalent bispecific antibody |
| GB0505971D0 (en) | 2005-03-23 | 2005-04-27 | Isis Innovation | Delivery of molecules to a lipid bilayer |
| NZ612578A (en) | 2005-08-19 | 2014-11-28 | Abbvie Inc | Dual variable domain immunoglobin and uses thereof |
| EP1945246A4 (en) * | 2005-09-22 | 2009-03-11 | Irun R Cohen | IMMUNOGENIC FRAGMENTS OF CONSTANT DOMAINS OF THE T CELL RECEPTOR AND PEPTIDES DERIVED THEREFROM |
| AU2008217578A1 (en) | 2007-02-20 | 2008-08-28 | Oxford Nanopore Technologies Limited | Lipid bilayer sensor system |
| PT2856876T (pt) | 2007-03-30 | 2018-03-28 | Memorial Sloan Kettering Cancer Center | Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos |
| WO2009051974A1 (en) * | 2007-10-17 | 2009-04-23 | Nuvelo, Inc. | Antibodes to cll-1 |
| EP2072527A1 (en) * | 2007-12-21 | 2009-06-24 | Altonabiotec AG | Fusion polypeptides comprising a SHBG dimerization component and uses thereof |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| EP4032552B1 (en) | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| DE102009045006A1 (de) | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
| US8956828B2 (en) * | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| EP2332994A1 (en) * | 2009-12-09 | 2011-06-15 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Trispecific therapeutics against acute myeloid leukaemia |
| US20130022629A1 (en) * | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| EP2614151B1 (en) | 2010-09-08 | 2019-07-24 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Interleukin 15 as selectable marker for gene transfer in lymphocytes |
| DK2614077T3 (en) | 2010-09-08 | 2016-11-21 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| WO2012050374A2 (en) | 2010-10-13 | 2012-04-19 | Innocell, Inc. | Immunotherapy for solid tumors |
| DK2632479T3 (en) * | 2010-10-27 | 2017-08-07 | Baxalta GmbH | FVIII PEPTIDES FOR IMMUNT TOLERANCE INDUCTION AND IMMUNODIAGNOSTICS |
| US20130337454A1 (en) | 2010-10-27 | 2013-12-19 | Philippe Duchateau | Method for increasing the efficiency of double-strand break-induced mutagenesis |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CA3179835A1 (en) | 2011-01-18 | 2012-07-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| SG10201602159VA (en) | 2011-02-11 | 2016-04-28 | Sloan Kettering Inst Cancer | Hla-restricted, peptide-specific antigen binding proteins |
| US8968539B2 (en) | 2011-03-08 | 2015-03-03 | Electronic Biosciences, Inc. | Methods for voltage-induced protein incorporation into planar lipid bilayers |
| CN110200997A (zh) * | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| WO2012134975A1 (en) | 2011-03-28 | 2012-10-04 | St. Jude Children's Research Hospital | Methods and compositions employing immunogenic fusion proteins |
| EP2694089B1 (en) | 2011-04-05 | 2024-06-05 | Cellectis | New tale-protein scaffolds and uses thereof |
| US9266960B2 (en) | 2011-04-08 | 2016-02-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer |
| US9285592B2 (en) | 2011-08-18 | 2016-03-15 | Google Inc. | Wearable device with input and output structures |
| BR112014006176A8 (pt) | 2011-09-16 | 2017-09-12 | Univ Pennsylvania | Rna transcrito in vitro ou rna sintético, composição, método para gerar uma população de células t geneticamente modificadas por rna, e, uso de uma célula t geneticamente modificada |
| CN104126009B (zh) | 2011-10-07 | 2019-05-10 | 国立大学法人三重大学 | 嵌合抗原受体 |
| KR102276792B1 (ko) * | 2011-10-10 | 2021-07-15 | 시티 오브 호프 | 메디토프와 메디토프-결합 항체 및 이들의 용도 |
| CN103946242A (zh) | 2011-10-20 | 2014-07-23 | 美国卫生和人力服务部 | 抗cd22嵌合抗原受体 |
| WO2013067492A1 (en) | 2011-11-03 | 2013-05-10 | The Trustees Of The University Of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
| WO2013070468A1 (en) | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| EP3456338B1 (en) * | 2011-11-15 | 2020-07-29 | The Walter and Eliza Hall Institute of Medical Research | Soluble cd52 for use in the treatment or prevention of multiple sclerosis or rheumatoid arthritis |
| WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| EP2817331B1 (en) | 2012-02-22 | 2023-08-30 | The Trustees of the University of Pennsylvania | Use of the cd2 signaling domain in second-generation chimeric antigen receptors |
| EA201491574A1 (ru) | 2012-02-22 | 2014-12-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Применение car, основанных на icos, для усиления противоопухолевой активности и длительного сохранения car |
| CN104159909A (zh) | 2012-02-22 | 2014-11-19 | 宾夕法尼亚大学董事会 | 产生用于癌症治疗的t细胞持续性群体的组合物和方法 |
| AU2013246443B2 (en) | 2012-04-11 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting B-cell maturation antigen |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US9163090B2 (en) | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| PL2855667T3 (pl) | 2012-05-25 | 2024-03-25 | Cellectis | Sposoby uzyskiwania metodami inżynierii allogenicznych i opornych na immunosupresję limfocytów t do immunoterapii |
| CN103483452B (zh) * | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| MX2015000426A (es) | 2012-07-13 | 2015-07-14 | Univ Pennsylvania | Incremento de actividad de celulas t car mediante cointroduccion de un anticuerpo biespecifico. |
| CN104507537A (zh) | 2012-07-13 | 2015-04-08 | 宾夕法尼亚大学董事会 | 用于调节car t细胞的组合物和方法 |
| CN104769103B (zh) | 2012-09-04 | 2018-06-08 | 塞勒克提斯公司 | 多链嵌合抗原受体和其用途 |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| TW201446794A (zh) * | 2013-02-20 | 2014-12-16 | Novartis Ag | 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向 |
| US9944690B2 (en) | 2013-03-14 | 2018-04-17 | Bellicum Pharmaceuticals, Inc. | Methods for controlling T cell proliferation |
| EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| AU2014240083C1 (en) | 2013-03-15 | 2019-10-24 | Celgene Corporation | Modified T lymphocytes |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| EP4364809A3 (en) | 2013-05-13 | 2024-07-24 | Cellectis | Cd19 specific chimeric antigen receptor and uses thereof |
| AU2014266833B2 (en) | 2013-05-13 | 2020-07-02 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
| ES2645393T3 (es) * | 2013-05-29 | 2017-12-05 | Cellectis | Métodos de manipulación de linfocitos T para inmunoterapia usando el sistema de nucleasa Cas guiada por ARN |
| ES2883131T3 (es) | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| MX2015016963A (es) * | 2013-06-10 | 2016-08-08 | Dana Farber Cancer Inst Inc | Metodos y composiciones para reducir la inmunosupresion por celulas de tumor. |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| HUE051523T2 (hu) | 2013-11-21 | 2021-03-01 | Ucl Business Ltd | Sejt |
| MX378635B (es) | 2013-11-22 | 2025-03-10 | Cellectis | Método para diseñar células t resistentes a fármacos de quimioterapia para inmunoterapia. |
| JP6942467B2 (ja) * | 2013-12-20 | 2021-10-06 | フレッド ハッチンソン キャンサー リサーチ センター | タグ化キメラエフェクター分子およびそのレセプター |
| JP2017504601A (ja) | 2013-12-20 | 2017-02-09 | セレクティスＣｅｌｌｅｃｔｉｓ | 免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法 |
| PL3105317T3 (pl) | 2014-02-14 | 2019-02-28 | Cellectis | Komórki do immunoterapii zaprojektowane do celowania antygenu obecnego zarówno na komórkach odpornościowych, jak i komórkach patologicznych |
| JP6772063B2 (ja) | 2014-02-14 | 2020-10-21 | ベリカム ファーマシューティカルズ， インコーポレイテッド | 誘導可能なキメラポリペプチドを使用して細胞を活性化するための方法 |
| EP3116902B1 (en) | 2014-03-11 | 2020-01-01 | Cellectis | Method for generating t-cells compatible for allogenic transplantation |
| WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| CN106103490B (zh) * | 2014-03-19 | 2020-03-03 | 塞勒克提斯公司 | 用于癌症免疫疗法的cd123特异性嵌合抗原受体 |
| US10316101B2 (en) * | 2014-04-14 | 2019-06-11 | Cellectis | BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy |
| AR101829A1 (es) * | 2014-07-21 | 2017-01-18 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1 |
| MX2017001011A (es) | 2014-07-21 | 2018-05-28 | Novartis Ag | Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma. |
| EP2990416B1 (en) * | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| BR112017011893A2 (pt) | 2014-12-05 | 2018-07-24 | City Of Hope | células t modificadas no receptor de antígeno quimérico direcionado para cs1 |
| PE20171653A1 (es) | 2015-04-13 | 2017-11-13 | Pfizer | Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b |
| US9668192B2 (en) | 2015-10-12 | 2017-05-30 | Telefonaktiebolaget Lm Ericsson (Publ) | Cell boundary crossing in a unidirectional SFN for high speed trains |
-
2016
- 2016-01-25 AU AU2016212158A patent/AU2016212158B2/en active Active
- 2016-01-25 CA CA2973532A patent/CA2973532A1/en not_active Abandoned
- 2016-01-25 US US15/546,623 patent/US20180051089A1/en not_active Abandoned
- 2016-01-25 KR KR1020177023447A patent/KR102661969B1/ko active Active
- 2016-01-25 EP EP16703450.3A patent/EP3250606B1/en active Active
- 2016-01-25 CN CN202111328553.6A patent/CN113968914A/zh active Pending
- 2016-01-25 JP JP2017557491A patent/JP2018504145A/ja active Pending
- 2016-01-25 AU AU2016212159A patent/AU2016212159A1/en not_active Abandoned
- 2016-01-25 EP EP16704136.7A patent/EP3250607A1/en not_active Withdrawn
- 2016-01-25 MX MX2017009349A patent/MX2017009349A/es unknown
- 2016-01-25 US US15/546,630 patent/US20180002435A1/en not_active Abandoned
- 2016-01-25 AU AU2016212160A patent/AU2016212160B2/en active Active
- 2016-01-25 CN CN202111329158.XA patent/CN113968915A/zh active Pending
- 2016-01-25 RU RU2017129591A patent/RU2732925C2/ru active
- 2016-01-25 WO PCT/EP2016/051469 patent/WO2016120218A1/en not_active Ceased
- 2016-01-25 JP JP2017557487A patent/JP6884709B2/ja active Active
- 2016-01-25 WO PCT/EP2016/051470 patent/WO2016120219A1/en not_active Ceased
- 2016-01-25 RU RU2017129592A patent/RU2731543C2/ru active
- 2016-01-25 JP JP2017557490A patent/JP2018504144A/ja not_active Withdrawn
- 2016-01-25 EP EP16703449.5A patent/EP3250605A1/en not_active Ceased
- 2016-01-25 DK DK16703450.3T patent/DK3250606T3/da active
- 2016-01-25 JP JP2017557488A patent/JP2018504143A/ja active Pending
- 2016-01-25 CN CN201680006972.9A patent/CN107406516B/zh active Active
- 2016-01-25 WO PCT/EP2016/051467 patent/WO2016120216A1/en not_active Ceased
- 2016-01-25 ES ES16703450T patent/ES2842212T3/es active Active
- 2016-01-25 CA CA2973525A patent/CA2973525C/en active Active
- 2016-01-25 US US15/546,633 patent/US11014989B2/en active Active
- 2016-01-25 ES ES16703448T patent/ES2869972T3/es active Active
- 2016-01-25 MX MX2017009182A patent/MX389057B/es unknown
- 2016-01-25 CN CN201680006922.0A patent/CN107438618A/zh active Pending
- 2016-01-25 WO PCT/EP2016/051471 patent/WO2016120220A1/en not_active Ceased
- 2016-01-25 EP EP16701616.1A patent/EP3250602A1/en not_active Withdrawn
- 2016-01-25 AU AU2016212162A patent/AU2016212162A1/en not_active Abandoned
- 2016-01-25 EP EP16703448.7A patent/EP3250604B1/en active Active
- 2016-01-25 DK DK16703448.7T patent/DK3250604T3/da active
- 2016-01-25 CA CA2973529A patent/CA2973529A1/en not_active Abandoned
- 2016-01-25 CN CN201680006992.6A patent/CN107531801B/zh active Active
- 2016-01-25 BR BR112017015453-6A patent/BR112017015453A2/pt not_active Application Discontinuation
- 2016-01-25 MX MX2017009181A patent/MX381908B/es unknown
- 2016-01-25 AU AU2016212161A patent/AU2016212161A1/en not_active Abandoned
- 2016-01-25 BR BR112017013981-2A patent/BR112017013981A2/pt active Search and Examination
- 2016-01-25 RU RU2017129455A patent/RU2017129455A/ru not_active Application Discontinuation
- 2016-01-25 US US15/546,619 patent/US20180002427A1/en not_active Abandoned
- 2016-01-25 KR KR1020177023078A patent/KR20170135824A/ko not_active Withdrawn
- 2016-01-25 WO PCT/EP2016/051468 patent/WO2016120217A1/en not_active Ceased
- 2016-01-25 CA CA2973524A patent/CA2973524A1/en not_active Abandoned
- 2016-01-25 US US15/546,604 patent/US20180000914A1/en not_active Abandoned
- 2016-01-25 JP JP2017557489A patent/JP6779909B2/ja active Active
- 2016-01-25 KR KR1020177021615A patent/KR102329836B1/ko active Active
-
2017
- 2017-06-15 IL IL252937A patent/IL252937B/en unknown
- 2017-06-19 IL IL253012A patent/IL253012A0/en unknown
- 2017-06-20 IL IL253049A patent/IL253049B/en unknown
-
2023
- 2023-10-05 US US18/481,797 patent/US20240228636A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504459A5 (Direct) | ||
| JP2018504143A5 (Direct) | ||
| JP7781243B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP2019530431A5 (Direct) | ||
| CN114773475B (zh) | Pd-1结合分子和其使用方法 | |
| TWI902089B (zh) | 引導及導航控制蛋白質以及彼之製造及使用方法 | |
| TWI758267B (zh) | 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法 | |
| CN107614013B (zh) | 结合lag-3的分子和其使用方法 | |
| JP2021177771A5 (Direct) | ||
| JP2018504144A5 (Direct) | ||
| JP2021087455A5 (Direct) | ||
| CN110035773B (zh) | 新型抗ctla4抗体 | |
| JP2018508219A5 (Direct) | ||
| RU2017129592A (ru) | АНТИ-CLL1-СПЕЦИФИЧЕСКИЕ ОДНОЦЕПОЧЕЧНЫЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ (scCAR) ДЛЯ ИММУНОТЕРАПИИ РАКА | |
| JP2020511136A5 (Direct) | ||
| JP2019527041A5 (Direct) | ||
| JP2018525033A5 (Direct) | ||
| JP2020514375A5 (Direct) | ||
| RU2017133637A (ru) | Иммуномодулирующие слитые белки и пути их применения | |
| JP2020515259A5 (Direct) | ||
| JP2020512973A5 (Direct) | ||
| JP2018504145A5 (Direct) | ||
| JP2024023228A5 (Direct) | ||
| CN107428833A (zh) | Ror1特异性抗体和嵌合抗原受体 | |
| HRP20241057T1 (hr) | Kimerni antigenski receptori na osnovu jedno-domenskih antitijela i načini njihove uporabe |